Name	: Ms. MOWMITA NANDY DE (41	(/F)	Date : 13/01/2024
Address	:		
Examined b	y:		UHID : AMHL.000208955
Package :	MEDIWHEEL - FULL BODY ANNI FEMALE HCK	UAL PLUS CHECK ADVANCE	AHC No : AMHLAH191866
	COMPLAINTS	Family history	
		Father	- alive
For corporate h	•	Aged	- 78
Shortness of bro	eath	Mother	- alive
Sneezing		Aged	- 68
Acidity		-	- 0
Visual disturban	ces	Brothers	
Back pain		Sisters	- 0
PRESENT KN	IOWN ILLNESS	Diabetes	- not known
No history of	- Hypertension	Hypertension	- mother
Hypertension	Since - 1 YR; Medica regular; - ORAL MED	tion - Coronary artery disease	- none
		Cancer	- None
•• · · · · · · · · · · · · · · · · · ·	ALLERGY	PHYSICAL EXAMIN	ATION
NO KNOWN ALLE	RGY :09/02/2023	🧟 General	
Net med	ical history	Height	- 153
Do you have an	v - No	Weight	- 62
allergies?	,	BMI	- 26.49
Covid 19	- No	Pallor	- No
		Oedema	- no
Surgical	history		
Caesarian secti	- on - 1	Cardiovascular s	system
Caesarian secti		Heart rate (Per minute)	- 66
Immunization h	istory	Rhythm	- Regular
	•	Systolic(mm of Hg)	- 146
	- Covid Dose1,Covid Do	Diastolic(mm of Hg)	- 92
			- B.P. Sitting
<b>T</b> Personal	nistory	Heart sounds	- S1S2+
Marital status	- Married		
No. of children	- 1	Respiratory system	
Female	- 1	Breath sounds	- Normal vesicular breath
Profession	- corporate employed		sounds
Diet	- Mixed Diet	Abdomen	
Alcohol	- does not consume alco	ohol	
Smoking	- No	Organomegaly	- No
Chews tobacco	- No	Tenderness	- No
Chews paan	- No	Ontheimeless	ation
Physical activity		Opthalmology consult	alion

Date : 13/01/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH191866

Opthalmology findings

- PGVA:RE:6/6 LE:6/6 BCVA:RE:N6 LE:N6 OCULAR MOVEMENT:WNL ANT.SEG:WNL ADVICE:\*To continue present glass Rx\*Review after 1yr/SOS

Printed By : Benazir Begaum

: 13/01/2024

Date

#### Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH191866

COMPLETE HAEMC	Result	Unit	Level	Range	Epithelial Cells	1-3			
Hemoglobin	14.3	g/dl	•	12.0-15.0	Casts:	Not Fou	Ind		
RBC COUNT	4.68	-	n/ 🔍	3.8-4.8	Crystals:	Not Fou	Ind		
		ul			<b>URINE SUGAR - POS</b>	T PRAN	DIAL		
Hematocrit - Hct:	41.0	%	•	36-46	(QUALITATIVE)				
MCV	87.7	fl	•	83-101	Test Name	Result	Unit	Level	Range
МСН	30.5	pg	٠	27-32	URINE GLUCOSE(POST	Nil			
МСНС	34.8 *	%	•	31.5-34.5	PRANDIAL)				
RDW	12.8	%	•	11.8-14.0			A I 1 <b>T</b> A		
WBC Count	9900	/cu m	ım 🔍	4000-10000	URINE SUGAR- FAST Test Name	Result			Range
Platelet Count	1.46 *	lacs/ mm	cu 💻	1.5-4.0	URINE GLUCOSE(FASTING)	Nil	onn	Lever	Runge
Neutrophils	69	%		40-80					
_ymphocytes	18 *	%	•	20-40	BLOOD GROUPING		•		
Vonocytes	06	%	٠	2-10	Test Name	Result	Unit	Level	Range
Eosinophils	07 *	%	•	01-06	ABO Group:	B			
Basophils	00	%	٠	0-0	Rh (D) Type:	POSITI	VE		
RBC:	Normoc	ytic No	rmochro	mic cells	LIVER FUNCTION TE	ST (PAC	KAGE	)	
VBC:	Eosinop	hilia no	ted		Test Name	Result	Unit	Level	Range
Platelets:	Adequa	te on th	e smeai	r	ALT(SGPT) - SERUM	26	U/L	•	0-35
ERYTHROCYTE SEDIMENTATION	12	mm/′ hr	Ist 🛡	0-20	ALBUMIN - SERUM	4.4	g/dL	•	3.5-5.1
RATE (ESR) RINE ROUTINE AN		SCOP	Ŷ		ALKALINE PHOSPHATASE - SERUM	89	U/L	•	33-98
Test Name	Result			Range					
/olume:	20	mL		_	AST (SGOT) - SERUM	28	U/L	٠	0-35
Colour:	Pale Str	aw							
Appearance	Slightly	Turbid			BILIRUBIN TOTAL - SERUM	0.5	mg/dl	- •	0.3-1.2
Specific Gravity	1.010								
oH:	6.5					•			_
Albumin:	Not Det	ected				Result			Range
Glucose	Not Det				CHOLESTEROL - SERUM	148	mg/dl		0-200
Ketone:	Not Det								
					CREATININE - SERUI				

Test Name	Result	Unit	Level	Range
CREATININE - SERUM	0.8	mg/dL	•	0.6-1.1

Pus Cells

RBC

**Bile Pigments** 

Within Normal Range

Nil

Not Detected

Occasionalhpf

/hpf

**Borderline High/Low** 

UHID : AMHL.0002089551

Date : 13/01/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH191866

LIVER FUNCTION TES	ST (PAC	KAGE	)		THYROID PROFILE -	I(T3,T4 /	AND T	SH)	
Test Name	Result	Unit	Level	Range	Test Name	Result	Unit	Level	Range
GGTP: GAMMA GLUTAMYL TRANSPEPTIDASE - SERUM	18	U/L	•	0-38	TOTAL T3: TRI IODOTHYRONINE - SERUM	0.89	ng/m		0.87-1.78
GLUCOSE - PLASMA	(FASTII	NG)			TOTAL T4: THYROXINE - SERUM	6.62	µg/dL	•	5.48-14.28
Test Name	Result	Unit	Level	Range					
GLUCOSE - PLASMA	100 *	mg/dl	•	70-99	LIPID PROFILE TEST	(PACKA	AGE)		
(FASTING)					Test Name	Result	Unit	Level	Range
GLUCOSE - PLASMA	DOST				TRIGLYCERIDES -	135	mg/d		0-150
Test Name	Result			Range	SERUM				
GLUCOSE - PLASMA	149 *	mg/dl	_	70-140	THYROID PROFILE -	I(T3 T4 /		SH)	
(POST PRANDIAL)	143	mg/ut		70-140	Test Name	Result			Range
					TSH: THYROID	1.53	μIU/n		0.38-5.33
HBA1C (GLYCOSYLA					STIMULATING				
HAEMOGLOBIN)-WHC			Laure	Danas	HORMONE - SERUM				
Test Name	Result		Level		URIC ACID - SERUM				
HBA1C (GLYCOSYLATED	5.3	%		Nondiadetic : 4 - 5.6 %	Test Name	Result	Unit	l evel	Range
HAEMOGLOBIN)-WHO LE BLOOD				Prediabetics : 5.7 - 6.4%	URIC ACID - SERUM	6.9 *	mg/d	_	2.4-5.7
				Diabetes : >/= 6.5%	LIVER FUNCTION TE	ST (PAC	KAGE	)	
				ADA	Test Name	Result	Unit	Level	Range
				Theraputic goal : <7%	BILIRUBIN CONJUGATED (DIRECT) - SERUM	0.1	mg/d		0.0-0.2
LIPID PROFILE TEST	(PACKA	AGE)							
Test Name	Result	Unit	Level	Range	BUN (BLOOD UREA	NITROG	EN)		
HDL CHOLESTEROL -	38	mg/dl	•	30-70	Test Name	Result	Unit	Level	Range
SERUM					BUN (BLOOD UREA NITROGEN)	8.1	mg/d		7.0-18.0
LDL CHOLESTEROL -SERUM	99	mg/dl	•	0-100	LIVER FUNCTION TE	ST (PAC	KAGE	)	
VLDL CHOLESTEROL -	11	mg/dl	•	0-35	Test Name	•			Range
SERUM (Calculated)		ing, ai	_	0-00	A/G - RATIO	1.2		٠	1.0-2.0
LIVER FUNCTION TES	ST (PAC	KAGE	)		BUN/CREATININE RA	σιτ			
Test Name	Result	Unit	Level	Range	Test Name	Result	Unit	Level	Range
PROTEIN TOTAL - SERUM	8.0	g/dL	•	6.4-8.3	BUN/CREATININE RATIO	10.8			
GLOBULIN:	3.6	g/dL	٠	1.8-3.6					
(CALCULATED) -					ECG				

: 13/01/2024

Date

### Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH191866

## SINUS RHYTHM. LOW VOLTAGE "QRS".

### **TREADMILL TEST / STRESS TEST**

STRESS TEST IS NEGATIVE FOR PROVOCABLE MYOCARDIAL ISCHAEMIA.

### ULTRASOUND SCREENING WHOLE ABDOMEN

- \* Grade I fatty liver.
- \* Elongated uterus.

[NOTE: At times pelvic structures are not well visualized due to inadequate patient preparation / excess bowel gas shadow. However suggested clinical correlation and other investigations if clinically indicated.]

Dr. PARTHA LODH DNB RESIDENT In consultation with

#### **X-RAY CHEST PA**

\* Chest skiagram does not reveal any significant abnormality.

Dr. KHWAJA KAMRUDDIN DNB RESIDENT In consultation with

X-RAY MAMMOGRAPHY BILATERAL (MHC)

Heterogeneously dense bilateral breast which may obscure small masses- BIRADS 0

Well circumscribed equal density lobulated lesion with foci of calcification seen in inner and upper quadrant of left breast and middle 1/3rd location-? fibroadenoma

Advise further evaluation by sonography

#### bIRADS Category:

- 0. Requires additional evaluation
- 1. Negative
- 2. Benign findings
- 3. Intermediate
- 4. Suspicious malignancy
- 5. Highly suggestive of malignancy
- 6: (Histo-pathologically proven)

--- END OF THE REPORT---

Dr. SUDESHNA MALAKAR MD, DNB, MNAMS, FRCR CONSULTANT RADIOLOGIST Reg. No ?" 70658 (WBMC)

INVESTIGATIONS NOT DONE / NOT YET REPORTED / NOT PART OF PACKAGE(LAB,RADIOLOGY & CARDIOLOGY)

**Out of Range** 

### Histopathology

PAP SMEAR /CERVICAL SMEAR



Borderline High/Low

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH191866

Printed By :

AHC Physician / Consultant Internal Medicine

Note :- The Health Check-up examinations and routine investigations have certain limitations and may not be able to detect all the diseases. Any new or persisting symptoms should be brought to the attention of the Consulting Physician. Additional tests, consultations and follow up may be required in some cases. Name : Ms. MOWMITA NANDY DE (41 /F)

UHID : AMHL.0002089551

: 13/01/2024

Date

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH191866

AICVD RISK SCORE REPORT					
RISK STATUS	YOUR SCORE	ACCEPTABLE SCORE			
Moderate Risk	4	4			

# Your likelihood of developing cardiovascular disease in the next ten years is 1.3 times higher than the people of your age and gender

The AICVD risk score developed by Apollo Hospitals is a novel artificial intelligence based risk scoring system that predicts your risk of having Coronary Artery Disease (CAD) related events in the next ten years. This scoring system uses Indian data and has been validated by multiple national and international institutions. This risk score is more than 92% accurate and has been compiled based on your physical parameters, heart health attributes, lifestyle and medical history. **Note:** The risk category is determined through the ratio between guest score and acceptable score at multiple decimal points. The outputs are shown in whole numbers.

#### Based on your AICVD risk score you are advised the following:

- Follow the guidance and education on lifestyle and dietary management provided through the ProHealth program. Maintain a healthy BMI (<25). Avoid tobacco in any form and if you are a smoker, stop smoking.
- Continue with medications for high blood pressure, diabetes, or dyslipidemia, if advised by your physician.Maintain HbA1c <7% (<53mmol/mol), blood pressure <140/90mmHg.</li>
- Follow your physician's advice regarding follow up tests, consults and annual health assessment
- It is recommended that you visit your physician every 6 months if you have:
  - o Uncontrolled high blood pressure, Diabetes, Dyslipidemia, Coronary heart disease

#### DISCLAIMER

- 1. This is not a diagnostic tool and it does not guarantee accuracy of the result and cannot be acted upon independently.
- 2. This risk score and clinical algorithm is a general guideline for physicians. Any additional laboratory investigations, diagnostic imaging,
- treatment or patient education related to lifestyle management is under the physician 's or cardiologist's discretion.
- 3. To ensure the information in the report is up to date, accurate and correct, doctor shall be consulted for interpretation of the report.
- 4. Apollo Hospitals and its staff does not offer any assurance on the information made available or be liable for any loss or damage as the said report is based on the AICVD risk score without any intervention from their side .
- 5. By usage of the AICVD risk score, it is deemed that the beneficiary of this service has agreed to get the same done at his own risk and further agrees with this disclaimer without any limitation or any clauses or sub-clauses.

# The Clinical AI Models and APIs used at Apollo Hospitals are certified by ISO 13485 : 2016 vide certificate no. MD 763515